Oncology Central

Exploring the CheckMate-227 study: an interview with Christiain Ottensmeier

Initial results from the Phase III CheckMate -227 study have been announced. The pivotal study has demonstrated that the combination of Opdivo® (nivolumab) plus Yervoy® (ipilimumab) can significantly extend progression-free survival (PFS) in those with previously untreated advanced non-small cell lung cancer (NSCLC) whose tumours have high tumour mutation burden (TMB). In this interview with CheckMate -227 trial investigator, Christian Ottensmeier (University of Southampton, UK), we explore the trial in more detail and see where the field is heading.
Could you give us a brief overview of the CheckMate -227 study?
Restricted Content / Members Only

You cannot view this content because It is available to members only. Please or Register to view this area.




News Headlines

Leave A Comment

Please wait...

Would you like access to more immuno-oncology content?

Register with Oncology Central to find out the latest news, opinions and journal articles published in the oncology field by leading experts.